Search

DexCom Inc

Closed

SectorHealthcare

86.95 -0.29

Overview

Share price change

24h

Current

Min

85.87

Max

87.73

Key metrics

By Trading Economics

Income

50M

249M

Sales

117M

1.3B

P/E

Sector Avg

34.51

68.51

EPS

0.7

Profit margin

19.039

Employees

11,000

EBITDA

52M

389M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+3.68% upside

Dividends

By Acuity

Next Earnings

29 paź 2026

Market Stats

By TradingEconomics

Market Cap

4.6B

33B

Previous open

87.24

Previous close

86.95

News Sentiment

By Acuity

21%

79%

64 / 340 Ranking in Healthcare

DexCom Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 sie 2026, 19:56 UTC

Dexcom Inc. shares are lower today, pulling back after reaching a session high. The broader market benefits from a significant decline in crude oil prices.

3 sie 2026, 20:02 UTC

News
Social Media

Dexcom Inc. shares are higher following strong Q2 results and raised revenue guidance to $5.22 billion. Canaccord increased its price target to $90.

31 lip 2026, 20:04 UTC

News
Social Media

Dexcom Inc. shares are higher following analyst upgrades and strong earnings, with second-quarter revenue of $1.31 billion exceeding expectations and guidance raised to $5.22 billion.

30 lip 2026, 23:51 UTC

News
Social Media

Dexcom reported second-quarter revenue of $1.308 billion and adjusted EPS of $0.70, raising its fiscal year 2026 revenue guidance, with shares trading higher in after-market hours.

29 lip 2026, 23:41 UTC

Dexcom Inc is trading higher in after-market hours, supported by overall market strength. The asset remains above its 20-day moving average.

28 lip 2026, 20:06 UTC

News

Dexcom shares rise after UBS initiated coverage with a Buy rating. The stock is advancing since Monday's close of $73.37 amid positive sentiment in the Health Care Equipment sector.

27 lip 2026, 19:06 UTC

News

Dexcom Inc. gains Health Canada approval for its Dexcom G7 continuous glucose monitoring system, boosting marketability and user adoption amid positive analyst sentiment.

24 lip 2026, 15:22 UTC

Dexcom Inc's shares are higher today, driven by gains in the Health Care Equipment sub-sector. No specific company news was identified for the movement.

22 lip 2026, 20:01 UTC

Dexcom Inc. shares are lower today, continuing a decline since Tuesday. Earlier, the stock briefly rose before pulling back.

21 lip 2026, 19:26 UTC

Dexcom Inc is trading lower, continuing a trend of three consecutive declines. The stock reached a session low earlier today before a slight recovery.

20 lip 2026, 19:22 UTC

Dexcom Inc shares are lower amid broader market declines and rising Treasury yields. The stock remains near the upper end of its one-month trading range.

Peer Comparison

Price change

DexCom Inc Forecast

Price Target

By TipRanks

3.68% upside

12 Months Forecast

Average 90.52 USD  3.68%

High 112 USD

Low 64 USD

Based on 23 Wall Street analysts offering 12 month price targets forDexCom Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

23 ratings

21

Buy

1

Hold

1

Sell

Sentiment

By Acuity

64 / 340 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
help-icon Live chat